Shares of Bionano Genomics (BNGO) plummeted over 20% on Wednesday after the genome analysis company announced a $3 million registered direct offering of common stock and warrants. The offering, priced at-the-market under Nasdaq rules, involved the sale of 9.88 million shares of common stock at $0.3039 per share.
Additionally, BNGO issued Series C warrants with a 5-year term and $0.3039 exercise price, as well as short-term Series D warrants with an 18-month term and the same $0.3039 exercise price, for up to 9.88 million shares each. If all warrants are exercised for cash, the company could raise up to an additional $6 million.
The steep stock price decline was likely a reaction to the potential dilution for existing shareholders from the equity offering and the complexity introduced by the warrant components. While the $3 million in gross proceeds provide BNGO with additional capital for general corporate purposes, including working capital, R&D, debt repayment, and capital expenditures, the offering represents a significant increase in the company's outstanding shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.